NRG Oncology Overview

Quynh Thu Le, MD
Stanford University
Disclosures

Research Funding
  • NCI, NIDCR, TRDRP, Varian, Amgen, GSK

Consulting/Advisory board
  • Varian, BMS, Merck, Grail, Genentech/Roche, Coherus, Nanobiotics

DSMB
  • Pfizer
Timeline of the NCTN System

2010

Institute of Medicine: Proposed Restructure of (and increased support for) the Group System.

NCI RFA: ‘Dissolve’ the Groups and plan for 4 ‘new’ adult Groups as part of a new Network

2012

Consolidation of the multiple Pediatric Cooperative Groups into COG.

2014

Assessment of the NCTN and Call for Competitive Renewal Applications

G o u p s  F u n d e d

2017-18

The 5 Groups renewed for 6-year funding cycle.

2019

NCI RFA: U10 Cooperative Agreement for NCI Clinical Trials Network

NCI: National Cancer Institute program
Goals of the NCTN (Cooperative Group) System

- Perform late-stage cancer trials that define standards of care for the U.S. and the world.
  - Available to broad constituency of diverse patients & investigators
  - Ensure all results (regardless of outcome) are published timely and objectively.
- Maintain high quality data repositories: clinical, imaging, biospecimen.
- Complement the research by non-N. American groups & industry
Some Facts about the NCTN Groups

- >2,000 participating sites in U.S./Canada + some international members -> >14,000 investigators.
- ~17,000 patients / year enrolled.
- ~$171 million / year budget.
- ~100 publications per year per Group.
- Proposed Group trials are rigorously reviewed (and approved or rejected) by NCI-sponsored Disease Steering Committees.

~$10,000 investment per patient

Courtesy Mitch Machtay
Population Diversity in Large Clinical Trials

%- Under-represented minority patients in several studies of common cancers.

<table>
<thead>
<tr>
<th>Study #</th>
<th>Disease/Stage</th>
<th>Total # Pts</th>
<th>% Black/African American</th>
<th>% Latino</th>
</tr>
</thead>
<tbody>
<tr>
<td>NRG RTOG 0534 (NCTN)</td>
<td>Postop Salvage Prostate</td>
<td>1,716</td>
<td>12.8%</td>
<td>4.3%</td>
</tr>
<tr>
<td>ARCHES (Enza-Pfizer/Astellas)</td>
<td>Met. HS Prostate</td>
<td>1,151</td>
<td>1.4%</td>
<td>Not stated</td>
</tr>
<tr>
<td>NRG NSABP B39/RTOG 0413 (NCTN)</td>
<td>Early breast CA</td>
<td>4,216</td>
<td>7%</td>
<td>4%</td>
</tr>
<tr>
<td>KEYNOTE-355 (Merck)</td>
<td>Advanced TNBC</td>
<td>847</td>
<td>4.5%</td>
<td>Not stated</td>
</tr>
<tr>
<td>NRG RTOG 0617 (NCTN)</td>
<td>Stage III Lung</td>
<td>465</td>
<td>11%</td>
<td>3%</td>
</tr>
<tr>
<td>PACIFIC (Astra Zeneca)</td>
<td>Stage III Lung</td>
<td>713</td>
<td>2%</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

Courtesy Mitch Machtay
Analysis of NCTN Impact on Life Years Added

• Unger et al. analyzed 163 ‘positive’ NCTN trials published 1980-2019.
  • Represents ~30% of completed NCTN trials
  • Includes 108,102 patients
  • Most common trials: Breast (33); GYN(28); Lung(15); Prostate(12).
• Model estimates that NCTN trials have added 14 million life years into U.S.
• Projection of 2030 estimate - 23 million life years saved.
NRG Oncology Foundation, Inc.

Board of Directors

External Scientific Advisory Board

Data Monitoring Committee

Group Chairs/Principal Investigators
Quynh-Thu Le, Robert S. Mannel, Norman Wolmark

NRG Oncology Foundation, Inc.

Voting Member Institutions

Statistics & Data Management Center*

Operations Center*

Deputy Group Chairs

Research Center
●Research Strategy Committee (RSC)
●Protocol Operations Management Committee
●RSC Executive Committee

Research Strategy Committee (RSC)

Non-Disease Site Scientific Committees

Scientific Core Committees

Cancer Disease Site Committees

Biospecimen Bank

Center for Innovation in Radiation Oncology (CIRO)

NSABP Foundation

RTOG Foundation

GOG Foundation

Non-Disease Site Scientific Committees

Quynh-Thu Le, Robert S. Mannel, Norman Wolmark

Operations Center*

Group Chairs/Principal Investigators

Deputy Group Chairs

Research Center

Research Strategy Committee (RSC)

Non-Disease Site Scientific Committees

Scientific Core Committees

Cancer Disease Site Committees

Biospecimen Bank

Center for Innovation in Radiation Oncology (CIRO)

External Scientific Advisory Board

Data Monitoring Committee

Group Chairs/Principal Investigators
Quynh-Thu Le, Robert S. Mannel, Norman Wolmark

Statistics & Data Management Center*

Operations Center*

Research Center
●Research Strategy Committee (RSC)
●Protocol Operations Management Committee
●RSC Executive Committee

Cancer Disease Site Committees

NRG Oncology

Biospecimen Bank

Center for Innovation in Radiation Oncology (CIRO)

NRG Oncology Center for Innovation in Radiation Oncology (CIRO)

Deputy Group Chairs

Quynh-Thu Le, Robert S. Mannel, Norman Wolmark
NRG Oncology Committees

**Research Center**
- Research Strategy Committee
- Protocol Operations Management Committee

**Cancer Disease Site Committees**
- Breast
- Brain
- Gastrointestinal
- Genitourinary
- Gynecologic
- Head & Neck
- Lung

**Non-Disease Site Scientific Committees**
- Developmental Therapeutics (DT)
- Cancer Prevention & Control (CPC)
- Patient Centered Outcomes Research (PCOR)
- Translational Science

**Scientific Core Committees**
- Ancillary Projects
- Health Disparities
- Imaging
- Medical Oncology
  - Immunotherapy
  - Pharmacy
- Pathology
- Patient Advocates
- Protocol Support
- Clinical Research Associates
- Nursing
- Radiation Oncology
- Medical Physics
- Surgical Oncology

**Administrative Committees**
- Communications
- Early Phase Trial Oversight
- Investigator Training
- Membership
- Publications

**Center for Innovation in Radiation Oncology (CIRO)**
NRG Oncology Scope

- Largest of the NCTN groups.
  - 1,900+ Participating members
  - 145 Main Member sites
  - 30 Lead Academic Participating Sites (LAPS)
  - 42 NCORPs + NCORP Mus

- Clinical trial portfolio
  - 45 trials activated / open to enrollment in the last funding cycle (3/14-2/19)
  - 45 trials activated / open to enrollment in the current funding cycle (3/19-6/22)
NRG Oncology past accomplishments

- Combined Modality superior to RT alone; usually worth the ↑ toxicity.
- IMRT and SBRT are feasible in multicenter studies & may improve outcome.
- Outcomes beyond OS, DFS, LRC and CTC-graded toxicity are essential.
- Addition of biologic agents to RT or chemoRT is generally safe.
- Treatment de-intensification is feasible for certain cancers (breast, head and neck)
- Sparing of critical regions is feasible and can improve function and QOL in patients (hippocampal sparing in brain mets)
- Recognition of molecular biomarkers as important in study design and outcomes.

Courtesy Mitch Machtay
NRG Oncology accomplishments in the last grant cycle

- Activated 34% of total number of 4 NCTN adult groups

- Enter 15,945 patients (33% of all entries) onto NCTN trials
  - 12.7% patients were African descent & 8.0% Latino or Hispanics

- 302 NRG peer-reviewed manuscripts - 52 contain practice-changing or practice-defining observations

- Received the best score on the competitive renewal
NRG Oncology’s Specific Patient Cohorts

- Patients with common or rare gender-specific malignancies, including gynecologic, prostate, or breast cancers, and/or

- Patients with localized or locally advanced malignancies including other GU malignancies or those originating in other sites, including the lungs, head and neck region, brain, or GI tract
NRG Oncology Specific Aims

• Investigate novel developments in medical technology, including radiation oncology, imaging, and surgery, for opportunities to test such developments in its multi-institutional clinical trials.

• Inform the design and execution of its phase II and III trials with employment of biomarker- and biologic pathway-defined approaches to risk stratification, investigational therapy assignment, and clinical trial decision-making.

• Apply the emerging knowledge in precision oncology and in immuno-oncology to the design and execution of its translational and clinical research efforts.
Future directions

Continue to expand on current themes but focusing on

• Theragnostics – combining imaging & therapy for new solid tumors with better dosimetric precision.

• Explore further hypofractionation in other disease sites.

• Define the role of proton beam therapy in solid tumors.

• Apply machine learning and artificial intelligence to RT planning, QA, and biomarker developments.

• Conduct more biomarker driven trials, especially using markers of minimal residual disease to guide therapy.

• Conduct more trials in precision oncology via the Combo-Match platform.

• Define now best to integrate immune oncology with local therapy (RT, surgery) and other systemic therapy (chemotherapy, targeted therapy)